Rotavirus vaccine and health care utilization for diarrhea in U.S. children

New England Journal of Medicine

Volumn 365, Issue 12, 2011, Pages 1108-1117

  Cortes, Jennifer E ^a   Curns, Aaron T ^a   Tate, Jacqueline E ^a   Cortese, Margaret M ^a   Patel, Manish M ^a   Zhou, Fangjun ^a   Parashar, Umesh D ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ROTAVIRUS VACCINE;

AGE DISTRIBUTION; ARTICLE; CHILD; CHILD HEALTH CARE; CHILD HOSPITALIZATION; CONTROLLED STUDY; COST CONTROL; DIARRHEA; DRUG EFFICACY; EMERGENCY CARE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; INFECTION RATE; OUTPATIENT CARE; PRESCHOOL CHILD; PRIORITY JOURNAL; RISK REDUCTION; ROTAVIRUS INFECTION; SEASONAL VARIATION; UNITED STATES; VACCINATION;

EID: 80053068639     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1000446     Document Type: Article

References (23)

1. Glass RI, Kilgore PE, Holman RC, et al. The epidemiology of rotavirus diarrhea in the United States: surveillance and estimates of disease burden. J Infect Dis 1996;174:Suppl 1:S5-S11. (Pubitemid 26293116)
2. Widdowson MA, Meltzer MI, Zhang X, Bresee JS, Parashar UD, Glass RI. Cost-effectiveness and potential impact of rotavirus vaccination in the United States. Pediatrics 2007;119:684-97. (Pubitemid 46556667)
3. Prevention of rotavirus gastroenteritis among infants and children: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006;55(RR-12):1-13.
4. Prevention of rotavirus gastroenteritis among infants and children: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2009;58(RR-2):1-25. [Erratum, MMWR Recomm Rep 2010;59(33):1074.]
5. Vesikari T, Matson DO, Dennehy P, et al. Safety and efficacy of a pentavalent human- bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006;354:23-33. (Pubitemid 43048948)
6. Block SL, Vesikari T, Goveia MG, et al. Efficacy, immunogenicity, and safety of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine at the end of shelf life. Pediatrics 2007;119:11-8. (Pubitemid 46397837)
7. Tate JE, Mutuc JD, Panozzo CA, et al. Sustained decline in rotavirus detections in the United States following the introduction of rotavirus vaccine in 2006. Pediatr Infect Dis J 2011;30:Suppl:S30-S34.
8. Clark HF, Lawley D, Mallette LA, Di- Nubile MJ, Hodinka RL. Decline in cases of rotavirus gastroenteritis presenting to The Children's Hospital of Philadelphia after introduction of a pentavalent rotavirus vaccine. Clin Vaccine Immunol 2009;16:382-6.
9. Payne DC, Szilagyi PG, Staat MA, et al. Secular variation in United States rotavirus disease rates and serotypes: implications for assessing the rotavirus vaccination program. Pediatr Infect Dis J 2009;28: 948-53. [Erratum, Pediatr Infect Dis J 2010; 29:287-8.]
10. Wang FT, Mast TC, Glass RJ, Loughlin J, Seeger JD. Effectiveness of the pentavalent rotavirus vaccine in preventing gastroenteritis in the United States. Pediatrics 2010;125(2):e208-e213.
11. Boom JA, Tate JE, Sahni LC, et al. Effectiveness of pentavalent rotavirus vaccine in a large urban population in the United States. Pediatrics 2010;125(2):e199-e207.
12. MarketScan. Ann Arbor, MI: Thomson Healthcare, 2008.
13. National Immunization Survey: estimated vaccination coverage, July 2008-June 2009. Atlanta: Centers for Disease Control and Prevention. (http://www.cdc.gov/vaccines/stats-surv/nis/data/tables-0809.htm.)
14. Rothman KJ, Greenland S. Modern epidemiology. 2nd ed. Philadelphia: Lippincott- Raven, 1998.
15. Consumer price indexes. Washington, DC: Bureau of Labor Statistics. (http://www.bls.gov/data.)
16. Cortese MM, Tate JE, Simonsen L, Edelman L, Parashar UD. Reduction in gastroenteritis in United States children and correlation with early rotavirus vaccine uptake from national medical claims databases. Pediatr Infect Dis J 2010;29:489-94.
17. Yen C, Tate JE, Wenk JD, Harris JM II, Parashar UD. Diarrhea-associated hospitalizations among US children over 2 rotavirus seasons after vaccine introduction. Pediatrics 2011;127(1):e9-e15.
18. Tate JE, Curns AT, Cortese MM, et al. Burden of acute gastroenteritis hospitalizations and emergency department visits in US children that is potentially preventable by rotavirus vaccination: a probe study using the now-withdrawn RotaShield vaccine. Pediatrics 2009;123:744-9.
19. Pitzer VE, Viboud C, Simonsen L, et al. Demographic variability, vaccination, and the spatiotemporal dynamics of rotavirus epidemics. Science 2009;325:290-4.
20. National Center for Health Statistics. VitalStats home page. (http://www.cdc.gov/nchs/vitalstats.htm.)
21. Buttery JP, Danchin MH, Lee KJ, et al. Intussusception following rotavirus vaccine administration: post-marketing surveillance in the National Immunization Program in Australia. Vaccine 2011;29: 3061-6.
22. Patel MM, Richardson López-Collada V, Mattos Bulhões M, et al. Intussusception risk and health benefits of rotavirus vaccination in Mexico and Brazil. N Engl J Med 2011;364:2283-92.
23. Cortese MM. Estimates of benefits and potential risks of rotavirus vaccination in the United States. Presented at the Advisory Committee on Immunization Practices Meeting, Atlanta, October 28, 2010. (http://www.cdc.gov/ vaccines/recs/acip/downloads/mtg-slides-oct10/12-3-rota-EstBenefitsRisks.pdf.)